ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Pooled it
- Association between blood neurofilament light chain levels and vascular cognitive impairment: a systematic review and meta-analysis.Frontiers in neuroscience · 2026Pooled it
- Beyond Amyloid: Systemic and Brain Frailty as Determinants of Response to Anti-Amyloid Therapy in Alzheimer's Disease-A Conceptual Review.Medicina (Kaunas, Lithuania) · 2026Review
- Plasma brain-derived p-Tau217 outperforms other p-Tau species in detecting abnormal brain amyloid in an Asian cohort of older people with cerebrovascular disease burden.The journal of prevention of Alzheimer's disease · 2026Observational
- Prospective study on physical activity and Alzheimer's disease-related biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Biomarker advancements in cerebral small vessel disease: An overview.Neural regeneration research · 2026Article
- From Bench to Bedside: Neurofilament Light Chain as a Biomarker in Ischemic Stroke.Current medical science · 2026Review
- Associations Between Cardiovascular Risk Factors and Neurofilament Light Levels Among US Mexican American Adults.Brain and behavior · 2026Article
- Cerebral microbleeds on susceptibility-weighted imaging, cognitive domains, and serum neurofilament light chain in adults with hypertension.Frontiers in neurology · 2026Article
- Comparison of the additive value of blood-based and retinal biomarkers to clinical features in predicting cognitive decline.Communications medicine · 2025Article
- Voxel-based morphometry reveals gray matter atrophy in cerebral small vessel disease: correlation with cognitive impairment.Quantitative imaging in medicine and surgery · 2025Article
- The role of Tau, amyloid-β and neuroinflammation in the association between cognition and white matter hyperintensities in a southeast Asian cohort.The journal of prevention of Alzheimer's disease · 2025Article
- The association between plasma and MRI biomarkers in dementia with lewy bodies.Alzheimer's research & therapy · 2025Article
- Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkers.JAMA network open · 2025Article
- Neurofilament Light Chain as a Biomarker of Global Cognition in Individuals With Possible Vascular Mild Cognitive Impairment.Journal of geriatric psychiatry and neurology · 2025Article
- Blood biomarkers for vascular cognitive impairment based on neuronal function: a systematic review and meta-analysis.Frontiers in neurology · 2025Review
- Associations of Circulating Platelet Endothelial Cell Adhesion Molecule-1 Levels With Progression of Cerebral Small-Vessel Disease, Cognitive Decline, and Incident Dementia.Journal of the American Heart Association · 2024Article
- Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.Alzheimer's research & therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Plasma neurofilament light chain (NfL) is a potential biomarker for neurodegeneration in Alzheimer's disease (AD), ischemic stroke, and non-dementia cohorts with cerebral small vessel disease (CSVD). However, studies of AD in populations with high prevalence of concomitant CSVD to evaluate associations of brain atrophy, CSVD, and amyloid beta (Aβ) burden on plasma NfL are lacking. Methods: Associations were tested between plasma NfL and brain Aβ, medial temporal lobe atrophy (MTA) as well as neuroimaging features of CSVD, including white matter hyperintensities (WMH), lacunes, and cerebral microbleeds. Results: We found that participants with either MTA (defined as MTA score ≥2; neurodegeneration [N]+WMH-) or WMH (cut-off for log-transformed WMH volume at 50th percentile; N-WMH+) manifested increased plasma NfL levels. Participants with both pathologies (N+WMH+) showed the highest NfL compared to N+WMH-, N-WMH+, and N-WMH- individuals. Discussion: Plasma NfL has potential utility in stratifying individual and combined contributions of AD pathology and CSVD to cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.